Burning Rock Biotech Limited (NASDAQ:BNR) shares sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. cut its holdings in shares of Burning Rock Biotech Limited (NASDAQ:BNR – Free Report) by 90.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 56,246 shares of the company’s stock after selling 535,182 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.55% of Burning Rock Biotech worth $363,000 at the end of the most recent reporting period.

Separately, Kynam Capital Management LP raised its position in Burning Rock Biotech by 10.9% in the first quarter. Kynam Capital Management LP now owns 9,640,914 shares of the company’s stock worth $7,020,000 after buying an additional 946,488 shares during the period. Hedge funds and other institutional investors own 30.03% of the company’s shares.

Burning Rock Biotech trading down 7.2%

NASDAQ BNR opened at $5.97 on Friday. The company’s 50-day moving average is $6.61, and its two-hundred-day moving average is $7.39. Burning Rock Biotech Limited has a 12-month low of $5.29 and a 12-month high of $14.80. The stock has a market cap of $61.16 million, a price-to-earnings ratio of -0.90 and a beta of 0.17.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report ) last posted its quarterly earnings results on Wednesday, May 29th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $17.40 million during the quarter. Burning Rock Biotech had a negative return on equity of 71.22% and a negative net margin of 113.39%.

Burning Rock Biotech Profile

(Free report)

Burning Rock Biotech Limited primarily develops and markets cancer therapy selection assays in the People’s Republic of China. It operates in three segments: Central Laboratory Business, Hospital Business and Pharmaceutical Research and Development Services. The company mainly provides state-of-the-art sequencing-based tissue and liquid biopsy cancer therapy selection tests and prognosis prediction tests for various cancers, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer. cancer, pancreatic cancer and bladder cancer using tissue and fluid biopsy samples.

Featured stories

Get news and reviews for Burning Rock Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Burning Rock Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.